Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan LYNOZYFIC Prior Auth | Open…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    LYNOZYFIC (linvoseltamab-gcpt) Coverage Criteria for Relapsed or Refractory Multiple Myeloma

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage for physician-administered intravenous LYNOZYFIC in adults with relapsed or refractory multiple myeloma. It establishes FDA-indication requirements, prior-treatment history, dosing, monitoring, site-of-care, and documentation requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyLYNOZYFIC (linvoseltamab-gcpt) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered IV LYNOZYFIC and document relapsed or refractory multiple myeloma, qualifying disease activity, and at least four prior therapy lines.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults ≥18Age requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥4 lines
    Required prior therapy
    200 mgStandard treatment dose
    6 monthsInitial authorization
    12 monthsReauthorization
    24 hoursStep-up dose observation

    Coverage Criteria

    Initial coverage criteria

    Covered when all of the following criteria are met:

    Core eligibility

    • Patient has relapsed or refractory multiple myeloma.
    • Treatment is prescribed by or in consultation with an oncologist.
    • Patient is age 18 years or older.Age ≥18 years
    • LYNOZYFIC is administered as a physician-administered intravenous infusion.

      Self-administration is not permitted.

    Disease activity

    • Measurable disease is documented within the last 28 days by serum M-protein ≥0.5 g/dL.Serum M-protein ≥0.5 g/dL assessed within the last 28 days
    • Measurable disease is documented within the last 28 days by urine M-protein ≥200 mg/24 hr.Urine M-protein ≥200 mg/24 hr assessed within the last 28 days
    • Measurable disease is documented within the last 28 days by an involved serum free light chain level ≥10 mg/dL.Involved serum free light chain ≥10 mg/dL assessed within the last 28 days
    • Progressive disease is documented under International Myeloma Working Group response criteria within 60 days following the last dose of the last anti-myeloma regimen.IMWG progressive disease assessed within 60 days

    Prior treatment exposure

    • Patient has received or has documented intolerance to at least four prior lines of multiple myeloma therapy.≥4 prior lines
    • Prior therapy includes at least one proteasome inhibitor.
    • Prior therapy includes at least one immunomodulatory agent.
    • Prior therapy includes at least one anti-CD38 monoclonal antibody.

    Exclusion screening

    • Patient does not have known multiple myeloma brain lesions or meningeal involvement.No known brain lesions or meningeal involvement

      These patients were excluded from the clinical trial.

    Dose support

    • Requested dose does not exceed the recommended dose for the current week of therapy.
    • Requested dose outside the recommended current-week schedule is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

      The prescriber must submit supporting evidence.

    Continuation therapy

    Continuation is authorized when treatment remains within the approved or medically accepted dosing schedule:

    Ongoing treatment

    • Continue LYNOZYFIC until disease progression or unacceptable toxicity.
    • Maintain the applicable treatment schedule for the current phase of therapy.

      Dose may be delayed, reduced, or permanently discontinued based on adverse-reaction severity.

    • Initial authorization or reauthorization remains active.Initial authorization: 6 months; reauthorization: 12 months

    Dosing schedule

    • Administer weekly doses at least five days apart.

    Coverage is not authorized for patients with known multiple myeloma brain lesions or meningeal involvement. These patients were excluded from the clinical trial supporting the policy.

    LYNOZYFIC must be administered by a physician as an intravenous infusion. Self-administration is not permitted; requests for treatment that will be self-administered do not meet coverage requirements.

    Coding and Clinical Documentation

    NDC CodesNDC
    61755-054-01LYNOZYFIC 5 mg/2.5 mL single-dose vial
    61755-0054-01LYNOZYFIC 5 mg/2.5 mL single-dose vial, 10-digit NDC
    61755-056-01LYNOZYFIC 200 mg/10 mL single-dose vial
    61755-0056-01LYNOZYFIC 200 mg/10 mL single-dose vial, 10-digit NDC
    HCPCS CodeHCPCSCovered
    C9307Injection, linvoseltamab-gcpt, 1 mg
    CPT Procedural CodesCPTCovered
    96413Chemotherapy IV infusion, up to one hour
    96415Chemotherapy IV infusion, additional hour; add-on code for every hour of infusion more than 30 minutes past the initial one hour
    Serum M-protein
    Threshold≥ 0.5 g/dL
    Assessment windowWithin the last 28 days
    Qualifying disease activityMeasurable disease evidenced by serum M-protein at or above the threshold
    Urine M-protein
    Threshold≥ 200 mg/24 hr
    Assessment windowWithin the last 28 days
    Qualifying disease activity

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Requirements

    Prior authorization is required for LYNOZYFIC (linvoseltamab-gcpt). Submit documentation showing physician-administered IV infusion, relapsed or refractory multiple myeloma, adult age, oncologist prescribing or consultation, qualifying disease activity, required prior therapy history, and no known multiple myeloma brain lesions or meningeal involvement.

    • Administer by physician-administered IV infusion; the drug cannot be self-administered.
    • Patient must be at least 18 years old.
    • Submit documentation of relapsed or refractory multiple myeloma.
    • Document that the prescriber is an oncologist or is prescribing in consultation with an oncologist.
    • Document qualifying measurable or progressive disease and the required prior treatment history.
    • Confirm absence of known multiple myeloma brain lesions or meningeal involvement.
    Note

    Authorization Duration

    Clinical Background

    LYNOZYFIC (linvoseltamab-gcpt) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that directs T-cell activity toward BCMA-expressing myeloma cells. It is indicated for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The indication received accelerated approval based on response rate and durability of response; continued approval may depend on confirmation of clinical benefit. Treatment has boxed-warning risks of cytokine release syndrome (CRS) and neurologic toxicities, including ICANS, and requires REMS availability and 24-hour hospitalization after the first two step-up doses.

    Key Definitions

    LYNOZYFIC
    ProductLYNOZYFIC (linvoseltamab-gcpt)
    Drug typeBispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
    MechanismDirects T-cell activity toward BCMA-expressing myeloma cells
    AdministrationPhysician-administered intravenous infusion
    CRS and ICANS
    CRSCytokine release syndrome; a potentially serious treatment-related reaction
    ICANSImmune Effector Cell-Associated Neurotoxicity Syndrome, a neurologic toxicity risk

    Initial Therapy

    Initial therapy criteria

    Initial therapy is covered when all required clinical, prior-treatment, dosing, administration, and safety criteria are met:

    Clinical eligibility and administration

    • Patient is an adult with relapsed or refractory multiple myeloma.
    • Patient is age 18 years or older.Age ≥18 years
    • LYNOZYFIC is prescribed by or administered in consultation with an oncologist.
    • LYNOZYFIC is administered by a physician as an intravenous infusion.

      LYNOZYFIC cannot be self-administered.

    Qualifying disease activity

    Continuation Therapy

    Continuation dosing

    Continuation therapy may be covered until disease progression or unacceptable toxicity when dosing remains within FDA labeling or accepted standards of medical practice:

    Ongoing continuation

    • Continue treatment until disease progression or unacceptable toxicity.
    • Maintain the applicable weekly, every-two-week, or every-four-week dosing schedule.
    • Dose remains within FDA-approved labeling or accepted standards of medical practice.

      Dose may be delayed, reduced, or permanently discontinued for adverse reactions.

    Schedule intervals

    • Weekly doses are administered at least five days apart.

    Required Prior Treatment Classes

    StepRequirementExamples
    1Before LYNOZYFIC, the patient must have received or documented intolerance to at least four prior lines of multiple myeloma therapy, including at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody.Proteasome inhibitors: bortezomib, Kyprolis, Ninlaro; immunomodulatory agents: Revlimid, Pomalyst, Thalomid; anti-CD38 monoclonal antibodies: Darzalex, Sarclisa.

    Dosing and Quantity Limits

    LYNOZYFIC quantity limits
    Step-up doses5 mg, 25 mg, and 200 mg
    Weekly dosing200 mg weekly for 10 treatment doses, from Weeks 4–13
    Every-two-week dosing200 mg every two weeks beginning at Week 14 and thereafter
    Every-four-week conversionAfter Week 24, 200 mg every four weeks for patients who achieve and maintain VGPR or better at or after Week 24 and have received at least 17 doses of 200 mg
    Minimum dosing intervalsWeekly doses at least 5 days apart; every-two-week doses at least 10 days apart; every-four-week doses at least 24 days apart

    Administration and Site-of-Care Requirements

    Billing Rule

    Administer in the physician office

    Administer LYNOZYFIC only as a physician-administered intravenous infusion. The drug cannot be self-administered.

    • Use the physician-administered IV route.
    • Do not dispense the drug for patient self-administration.
    Note

    Arrange required post-dose hospitalization

    Hospitalize the patient for 24 hours after administration of the Day 1 and Day 8 step-up doses because of the risk of cytokine release syndrome and neurologic toxicity, including ICANS.

    • Apply the 24-hour hospitalization requirement after both Day 1 and Day 8 step-up doses.
    • The step-up doses are 5 mg on Day 1 and 25 mg on Day 8.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyLYNOZYFIC (linvoseltamab-gcpt) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered IV LYNOZYFIC and document relapsed or refractory multiple myeloma, qualifying disease activity, and at least four prior therapy lines.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical DocumentationAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsInitial TherapyContinuation TherapyRequired Prior Treatment ClassesDosing and Quantity LimitsAdministration and Site-of-Care Requirements
    Weekly doses ≥5 days apart
  1. Administer every-two-week doses at least 10 days apart.Every-two-week doses ≥10 days apart
  2. For a patient who has achieved and maintained VGPR or better at or after Week 24 and has received at least 17 doses of 200 mg, administer 200 mg every four weeks.VGPR or better at or after Week 24; ≥17 doses of 200 mg; 200 mg every 4 weeks
  3. Administer every-four-week doses at least 24 days apart.Every-four-week doses ≥24 days apart
  4. Measurable disease evidenced by urine M-protein at or above the threshold
    Involved serum free light chain
    Threshold≥ 10 mg/dL
    Assessment windowWithin the last 28 days
    Qualifying disease activityMeasurable disease evidenced by an involved serum free light chain level at or above the threshold
    Progressive disease assessment
    Assessment standardProgressive disease as defined by International Myeloma Working Group (IMWG) response criteria
    Assessment windowWithin 60 days following the last dose of the last anti-myeloma drug regimen received
    Coverage pathwayQualifying progressive disease is an alternative to measurable disease documentation

    Initial authorization is available for six months; reauthorization is available for 12 months. Dosing must follow FDA-approved labeling or accepted standards of medical practice, including the recommended dose for the current week of therapy unless supporting evidence is submitted for an off-label dose.

    • Initial authorization: six months.
    • Reauthorization: 12 months.
    • Dose approval follows FDA-approved labeling or accepted standards of medical practice.
    • The current-week dosing schedule applies throughout the authorization period.

    Unsupported block type: step_therapy

    Documentation Required

    Patient and Prescriber Information

    The authorization submission must identify the patient’s diagnosis and age and identify the prescribing oncologist or consulting oncologist. Include consultation documentation when the prescriber is not the oncologist.

    • Relapsed or refractory multiple myeloma diagnosis.
    • Patient age of 18 years or older.
    • Prescribing oncologist or documented oncologist consultation.
    Documentation Required

    Disease Activity Documentation

    Document disease activity using an assessment performed within the applicable timeframe. The patient must have either measurable disease assessed within the last 28 days or progressive disease under International Myeloma Working Group response criteria assessed within 60 days after the last dose of the last anti-myeloma regimen.

    • Serum M-protein ≥ 0.5 g/dL, assessed within the last 28 days; or
    • Urine M-protein ≥ 200 mg/24 hr, assessed within the last 28 days; or
    • Involved serum free light chain level ≥ 10 mg/dL, assessed within the last 28 days; or
    • Progressive disease as defined by IMWG response criteria, assessed within 60 days following the last dose of the last anti-myeloma drug regimen.
    Documentation Required

    Prior Treatment History

    Submit a complete prior-treatment record supporting at least four prior lines and documented intolerance. The record should identify the regimens used and demonstrate exposure to the required therapy classes.

    • Include dates, regimen names, and treatment outcomes or intolerance for each qualifying line.
    • Qualifying examples include regimens containing bortezomib, Kyprolis, Ninlaro, Revlimid, Pomalyst, Thalomid, Darzalex, Sarclisa, Empliciti, or commonly used combination regimens listed in the guideline.
    • The history must include a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
    Documentation Required

    Off-Label Dose Support

    If the requested dose exceeds the recommended dose for the current week of therapy, the prescriber must submit supporting evidence. Acceptable support is a relevant practice guideline or peer-reviewed literature addressing the off-label use or dose.

    • Submit the specific requested dose and treatment schedule.
    • Provide the applicable practice guideline or peer-reviewed publication.
    • The prescriber is responsible for submitting the supporting evidence with the authorization request.
    Documentation Required

    Pregnancy Risk Documentation

    Because LYNOZYFIC can cause fetal harm, verify pregnancy status in females of reproductive potential before treatment begins. Counsel these patients to use effective contraception during treatment and for three months after the last dose.

    • Document pregnancy verification before initiating treatment when applicable.
    • Document contraception counseling for females of reproductive potential.
    • Effective contraception is advised during treatment and for three months after the last dose.
    Denial Risk

    Failure to Meet Clinical Eligibility

    Coverage may be denied when the request does not meet the core clinical eligibility requirements or represents a non-covered use. LYNOZYFIC is not covered under these criteria for patients younger than 18 years or for conditions other than relapsed or refractory multiple myeloma.

    • Diagnosis is not relapsed or refractory multiple myeloma.
    • Patient is younger than 18 years.
    • Use is not supported by the covered indication or is otherwise non-covered.
    • Known multiple myeloma brain lesions or meningeal involvement are present.
    Denial Risk

    Insufficient Disease or Treatment History

    Authorization may be denied when required disease activity or treatment history is not established. The request must include qualifying measurable disease or recent IMWG-defined progressive disease and documentation of at least four prior lines with the required therapy classes.

    • No measurable disease meeting the specified serum M-protein, urine M-protein, or involved FLC threshold within the required 28-day period.
    • No progressive disease assessment under IMWG criteria within 60 days following the last dose of the last anti-myeloma regimen.
    • Fewer than four qualifying prior lines or insufficient documentation of documented intolerance.
    • Prior therapy history does not include a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.
    Denial Risk

    Unsupported Dose

    A dose above the recommended dose for the current week of therapy may be denied unless the prescriber submits supporting practice guidelines or peer-reviewed literature for the relevant off-label use.

    • The requested dose must not exceed the current-week recommended dose without supporting evidence.
    • FDA-approved labeling or accepted standards of medical practice must support the requested dosing.
    Denial Risk

    Improper Administration

    LYNOZYFIC must be administered as a physician-administered IV infusion. Requests for self-administration or administration outside the required physician-administered IV setting may be denied.

    • Self-administration is not permitted.
    • Administration must be by IV infusion under physician administration.
    Monitoring requirementPatients should be monitored for CRS and neurologic toxicity, including ICANS
    Step-up observationHospitalization for 24 hours is required after Day 1 and Day 8 step-up doses because of CRS and neurologic-toxicity risk
    • Measurable disease is documented within the preceding 28 days by serum M-protein ≥0.5 g/dL.
    • Measurable disease is documented within the preceding 28 days by urine M-protein ≥200 mg/24 hr.
    • Measurable disease is documented within the preceding 28 days by involved serum free light chain ≥10 mg/dL.
    • Progressive disease is documented according to International Myeloma Working Group response criteria within 60 days following the last dose of the last anti-myeloma drug regimen.

    Prior treatment requirements

    • Patient has received or has documented intolerance to at least four prior lines of therapy.≥4 prior lines
    • Prior therapy includes one proteasome inhibitor, such as bortezomib, Kyprolis, or Ninlaro.
    • Prior therapy includes one immunomodulatory agent, such as Revlimid, Pomalyst, or Thalomid.
    • Prior therapy includes one anti-CD38 monoclonal antibody, such as Darzalex or Sarclisa.

    Safety and dosing

    • Patient does not have known multiple myeloma brain lesions or meningeal involvement.No known CNS exclusion
    • Dose authorization

      • Requested dose does not exceed the recommended dose for the current week of therapy.
      • Requested off-label dose is supported by practice guidelines or peer-reviewed literature, with supporting evidence submitted by the prescriber.
    • Patient is hospitalized for 24 hours after administration of the Day 1 and Day 8 step-up doses.24-hour hospitalization after Day 1 and Day 8 step-up doses

      Required because of cytokine-release syndrome and neurologic-toxicity risk.

    ≥5 days apart
  5. Every-two-week doses are administered at least 10 days apart.≥10 days apart
  6. Every-four-week doses are administered at least 24 days apart when that schedule applies.≥24 days apart
  7. Every-four-week conversion

    • Patient has achieved and maintained a very good partial response (VGPR) or better at or after Week 24.VGPR or better at or after Week 24
    • Patient has received at least 17 doses of 200 mg.≥17 doses of 200 mg